The historical rank and industry rank for Piramal Pharma's FCF Margin % or its related term are showing as below:
NSE:PPLPHARMA'
s FCF Margin % Range Over the Past 10 Years
Min: -6.84 Med: 2.49 Max: 8.6
Current: 8.6
During the past 6 years, the highest FCF Margin % of Piramal Pharma was 8.60%. The lowest was -6.84%. And the median was 2.49%.
NSE:PPLPHARMA's FCF Margin % is ranked better than 66.81% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs NSE:PPLPHARMA: 8.60
Piramal Pharma FCF Margin % Related Terms
Piramal Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Piramal Pharma and its competitors. According to the industry distribution chart, Piramal Pharma ranks #317 out of 955 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Piramal Pharma's FCF Margin % too high?
Piramal Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Piramal Pharma ranks #317 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #317 out of 955 companies for FCF Margin %. This puts Piramal Pharma in the upper half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.28, compared to a current price of ₹167.69 — trading 4.3% below its estimated fair value. The current FCF Margin % is 0.00%. Piramal Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued.
The current stock price of ₹167.69 is trading 4.3% below its estimated GF Value™ of ₹175.28.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
FCF Margin %: 0.00%
GF Value™: ₹175.28 vs. price of ₹167.69 (4.3% below fair value)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score
Get the complete analysis for NSE:PPLPHARMA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
